
## Sandrine Imbeaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1648099/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut, 2022, 71, 616-626.	6.1	106
2	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncology, The, 2022, 23, 161-171.	5.1	36
3	Structure, Dynamics, and Impact of Replication Stress–Induced Structural Variants in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 1470-1481.	0.4	0
4	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology, 2021, 74, 816-834.	3.6	20
5	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology, 2020, 71, 164-182.	3.6	129
6	Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut, 2020, 69, 737-747.	6.1	78
7	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut, 2020, 69, 1667-1676.	6.1	17
8	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. Journal of Hepatology, 2020, 72, 924-936.	1.8	44
9	Genetic alterations of malignant pleural mesothelioma: associationÂwith tumor heterogeneity and overall survival. Molecular Oncology, 2020, 14, 1207-1223.	2.1	74
10	Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. Gastroenterology, 2019, 157, 807-822.	0.6	22
11	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776.	0.6	141
12	<i>APC</i> germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Oncolmmunology, 2019, 8, e1583547.	2.1	31
13	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. International Journal of Cancer, 2019, 144, 533-544.	2.3	72
14	Netrin G1: its downregulation in the nucleus accumbens of cocaineâ€conditioned mice and genetic association in human cocaine dependence. Addiction Biology, 2018, 23, 448-460.	1.4	3
15	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nature Communications, 2018, 9, 5235.	5.8	118
16	Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics, 2018, 34, 3380-3381.	1.8	53
17	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity <i>In Vitro</i> . Clinical Cancer Research, 2017, 23, 4364-4375.	3.2	57
18	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. Journal of Hepatology, 2017, 67, 727-738.	1.8	525

SANDRINE IMBEAUD

#	Article	IF	CITATIONS
19	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. Journal of Hepatology, 2017, 66, 734-742.	1.8	31
20	Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	0.6	290
21	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nature Communications, 2017, 8, 1315.	5.8	228
22	Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. Cancers, 2017, 9, 101.	1.7	56
23	aCNViewer: Comprehensive genome-wide visualization of absolute copy number and copy neutral variations. PLoS ONE, 2017, 12, e0189334.	1.1	5
24	Genotypeâ€phenotype correlation of CTNNB1 mutations reveals different ß atenin activity associated with liver tumor progression. Hepatology, 2016, 64, 2047-2061.	3.6	222
25	A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nature Medicine, 2016, 22, 744-753.	15.2	207
26	Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. Molecular and Cellular Oncology, 2016, 3, e1095271.	0.3	12
27	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. Molecular Therapy, 2016, 24, 660-661.	3.7	33
28	AAV2 and Hepatocellular Carcinoma. Human Gene Therapy, 2016, 27, 211-213.	1.4	8
29	Abstract 112: Genetic alterations in molecular tumor subgroups of malignant pleural mesothelioma. , 2016, , .		1
30	DNA methylationâ€based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 2015, 61, 1945-1956.	3.6	367
31	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 806-818.e10.	0.6	109
32	Authors' response: virus–host interactions in HBV-related hepatocellular carcinoma: more to be revealed?. Gut, 2015, 64, 853-854.	6.1	11
33	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 2015, 47, 505-511.	9.4	1,372
34	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nature Genetics, 2015, 47, 1187-1193.	9.4	387
35	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut, 2015, 64, 820-829.	6.1	127
36	Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2014, 20, 1323-1334.	3.2	121

#	Article	IF	CITATIONS
37	Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. Clinical Cancer Research, 2014, 20, 3338-3347.	3.2	98
38	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. Cancer Cell, 2014, 25, 428-441.	7.7	240
39	Functional Study of the Hap4-Like Genes Suggests That the Key Regulators of Carbon Metabolism HAP4 and Oxidative Stress Response YAP1 in Yeast Diverged from a Common Ancestor. PLoS ONE, 2014, 9, e112263.	1.1	8
40	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	13.7	8,060
41	Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology, 2013, 58, 229-238.	3.6	172
42	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	0.6	302
43	Recurrent inactivating mutations of <i>ARID2</i> in nonâ€small cell lung carcinoma. International Journal of Cancer, 2013, 132, 2217-2221.	2.3	70
44	Comparative Transcriptomic Analysis of Salt Adaptation in Roots of Contrasting Medicago truncatula Genotypes. Molecular Plant, 2012, 5, 1068-1081.	3.9	75
45	Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. Journal of Hepatology, 2012, 56, 869-876.	1.8	53
46	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics, 2012, 44, 694-698.	9.4	1,229
47	Next-generationsequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. Oncolmmunology, 2012, 1, 1612-1613.	2.1	24
48	Genome-Wide Gene Expression Profiling of Fertilization Competent Mycelium in Opposite Mating Types in the Heterothallic Fungus Podospora anserina. PLoS ONE, 2011, 6, e21476.	1.1	51
49	Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2. Neuro-Oncology, 2011, 13, 1125-1132.	0.6	19
50	A general framework for optimization of probes for gene expression microarray and its application to the fungus Podospora anserina. BMC Research Notes, 2010, 3, 171.	0.6	16
51	Loss of hepatocyte nuclear factor 1α function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology, 2010, 51, 557-566.	3.6	66
52	SMARCA2 and other genome-wide supported schizophrenia-associated genes: regulation by REST/NRSF, network organization and primate-specific evolution. Human Molecular Genetics, 2010, 19, 2841-2857.	1.4	78
53	Identification of Novel Oncogenes and Tumor Suppressors in Hepatocellular Carcinoma. Seminars in Liver Disease, 2010, 30, 075-086.	1.8	75
54	A Functional and Regulatory Network Associated with PIP Expression in Human Breast Cancer. PLoS ONE, 2009, 4, e4696.	1.1	31

SANDRINE IMBEAUD

#	Article	IF	CITATIONS
55	DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Human Molecular Genetics, 2009, 18, 1405-1414.	1.4	128
56	Global Analysis of Extracytoplasmic Stress Signaling in Escherichia coli. PLoS Genetics, 2009, 5, e1000651.	1.5	209
57	Mutations in the Saccharomyces cerevisiae Kinase Cbk1p Lead to a Fertility Defect That Can Be Suppressed by the Absence of Brr1p or Mpt5p (Puf5p), Proteins Involved in RNA Metabolism. Genetics, 2009, 183, 161-173.	1.2	13
58	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 2009, 457, 200-204.	13.7	437
59	Genomic Consequences of Cytochrome P450 2C9 Overexpression in Human Hepatoma Cells. Chemical Research in Toxicology, 2009, 22, 779-787.	1.7	8
60	Response of human renal tubular cells to cyclosporine and sirolimus: A toxicogenomic study. Toxicology and Applied Pharmacology, 2008, 229, 184-196.	1.3	51
61	The β-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. Journal of Hepatology, 2008, 49, 61-71.	1.8	87
62	HNF1α Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation. Journal of Biological Chemistry, 2007, 282, 14437-14446.	1.6	123
63	The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Research, 2007, 36, D793-D799.	6.5	57
64	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology, 2007, 46, 740-748.	3.6	554
65	Deciphering cellular states of innate tumor drug responses. Genome Biology, 2006, 7, R19.	13.9	110
66	Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood, 2006, 107, 1582-1590.	0.6	91
67	†The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments. Drug Discovery Today, 2005, 10, 1175-1182.	3.2	61
68	XX sex reversal, palmoplantar keratoderma, and predisposition to squamous cell carcinoma: Genetic analysis in one family. American Journal of Medical Genetics, Part A, 2005, 138A, 241-246.	0.7	37
69	Functional coupling of adenine nucleotide translocase and mitochondrial creatine kinase is enhanced after exercise training in lung transplant skeletal muscle. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 289, R1144-R1154.	0.9	56
70	Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Research, 2005, 33, e56-e56.	6.5	437
71	Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7653-7658.	3.3	240
72	Functional Annotation: Extracting functional and regulatory order from microarrays. Molecular Systems Biology, 2005, 1, 2005.0009.	3.2	8

SANDRINE IMBEAUD

#	Article	IF	CITATIONS
73	Integrative Annotation of 21,037 Human Genes Validated by Full-Length cDNA Clones. PLoS Biology, 2004, 2, e162.	2.6	290
74	The Human Anatomic Gene Expression Library (H-ANGEL), the H-Inv integrative display of human gene expression across disparate technologies and platforms. Nucleic Acids Research, 2004, 33, D567-D572.	6.5	16
75	From functional genomics to systems biology: concepts and practices. Comptes Rendus - Biologies, 2003, 326, 879-892.	0.1	103
76	Self–organized living systems: conjunction of a stable organization with chaotic fluctuations in biological space–time. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2003, 361, 1125-1139.	1.6	29
77	INCONSISTENCIES BETWEEN MAPS OF HUMAN CHROMOSOME 22 CORRELATE WITH INCREASED FREQUENCY OF DISEASE-RELATED LOCI. Journal of Biological Systems, 2002, 10, 303-317.	0.5	2
78	Autosomal Recessive Segregation of a Truncating Mutation of Anti-Müllerian Type II Receptor in a Family Affected by the Persistent Müllerian Duct Syndrome Contrasts with Its Dominant Negative Activityin Vitro. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4390-4397.	1.8	20
79	Clinical aspects and molecular genetics of the persistent Müllerian duct syndrome. Clinical Endocrinology, 1997, 47, 137-144.	1.2	58
80	Mutant Isoforms of the Anti-Müllerian Hormone Type II Receptor Are Not Expressed at the Cell Membrane. Journal of Biological Chemistry, 1996, 271, 30571-30575.	1.6	44
81	Testicular degeneration in three patients with the persistent müllerian duct syndrome. European Journal of Pediatrics, 1995, 154, 187-190.	1.3	27
82	Insensitivity to anti–Müllerian hormone due to a mutation in the human anti–Müllerian hormone receptor. Nature Genetics, 1995, 11, 382-388.	9.4	212
83	The Gene for Anti-Müllerian Hormone. , 1994, , 439-455.		2
84	Surgical and genetic aspects of persistent müllerian duct syndrome. Journal of Pediatric Surgery, 1994, 29, 61-65.	0.8	71
85	The persistent Müllerian duct syndrome: A rare cause of cryptorchidism. European Journal of Pediatrics, 1993, 152, S76-S78.	1.3	28
86	Anti-Müllerian Hormone: The Jost Factor. , 1993, 48, 1-59.		195
87	Variants of the anti-Mïį½llerian hormone gene in a compound heterozygote with the persistent Mïį¼llerian duct syndrome and his family. Human Genetics, 1992, 90, 389-94.	1.8	61